Hybrid Immunity

Humoral and cellular responses to SARS-CoV-2 vaccination in pediatric acute lymphoblastic leukemia patients

Tania Watts, University of Toronto

This study aims to characterize immunity to SARS-CoV-2 in pediatric acute lymphoblastic leukemia (ALL) patients six months or older on maintenance chemotherapy and post CAR-T therapy to evaluate vaccine immunogenicity. The goal is to understand whether children with ALL have lower SARS-CoV-2 vaccine-induced seroconversion rates and higher rates of breakthrough infections leading to severe outcomes.
Research summary

Determining the impact of hybrid immunity on the evolving landscape of host responses to SARS-CoV-2 in the Biobanque Québécoise de la COVID-19 (BQC19)

Madeleine Durand and Simon Rousseau, McGill University

The BQC19 is recruiting 500 new participants who are assigned to exposure groups according to whether or not they have been vaccinated and have had a prior infection with the goal of studying the impact of hybrid immunity on outcomes.
Research summary

SUrveying Prospective Population cOhorts for COVID19 pRevalence and ouTcomes in Canada (SUPPORT-Canada) – Hybrid Immunity Extension

Philip Awadalla, Canadian Partnership for Tomorrow’s Health (CanPath)

Using the third of participants from the COVID-19 in Long-Term Care study who have hybrid immunity (almost half infected with Omicron), this project will do additional blood collection from participants to better assess immune protection and longevity against evolving SARS-CoV-2 variants by vaccine type, additional vaccine doses, and hybrid immunity across variant lineages.
Research summary

Dawn Bowdish
Dawn Bowdish

COVID-19 Infection and Immunity in Residents of Long-term Care Facilities: Hybrid Immunity in Residents of Long-term Care Facilities

Andrew Costa and Dawn Bowdish, McMaster University

Using the third of participants from the COVID-19 in Long-Term Care study who have hybrid immunity (almost half infected with Omicron), this project will do additional blood collection from participants to better assess immune protection and longevity against evolving SARS-CoV-2 variants by vaccine type, additional vaccine doses, and hybrid immunity across variant lineages.
Research summary

Safety and immUnogenicity of Covid-19 vaCcines in systEmic immunE mediated inflammatory Diseases: Infections and Immunity (SUCCEED-II) – Hybrid Immunity Extension

Sasha Bernatsky, Research Institute of the McGill University Health Centre (RI-MUHC)

An extension of the SUCCEED study, this project will look at how vaccination and COVID-19 infection jointly affect hybrid immunity in adults who have autoimmune diseases such as rheumatoid arthritis, spondyloarthritis, inflammatory bowel disease, psoriasis, and other conditions.
Research summary

Long-term impact of COVID-19 infection and immunity in education workers

Pascal Lavoie, University of British Columbia

This study, an extension of one focussing on education workers in Vancouver, aims to determine how immunity conferred by hybrid immunity differs from the immunity conferred by an infection alone, to compare re-infection rates between individuals with hybrid versus vaccine immunity; and to determine the long-term health impact of SARS-CoV-2 infections among school staff.
Research summary

Deconstructing hybrid immune responses to SARS-CoV-2 in older adults and people living with HIV

Marc Romney, University of British Columbia

This study will perform longitudinal characterizations of vaccine-induced immunity vs. hybrid immunity. It will quantify binding antibodies, virus neutralizing activity, as well as B cell and T cell responses against wild-type and Omicron spike proteins and explore features of B cells and T cells that determine antiviral activity and specificity.
Research summary

Characterization of humoral response in blood donors vaccinated against SARS-CoV-2 and then infected with variants of concern

Renée Bazin and Andrés Finzi, Héma-Québec

This study is evaluating the antibody response induced in participants vaccinated against SARS-CoV-2 and then infected with recently identified variants of concern to provide information on the type, duration of immunity and level of protection. Researchers are also studying the immunity induced by the new bivalent vaccines against SARS-CoV-2.
Research summary

Characterization of Hybrid Cellular and Humoral Immunity against SARS-CoV-2 and Evaluation of its Role in Protection from Infection and from Severe Illness

Michael Grant, Memorial Universty of Newfoundland

This study compares SARS-CoV-2 immunological and infectious outcomes between vaccinated individuals with 2 to 4 doses of a licensed vaccine, persons infected prior to vaccination who have now received 2 to 4 doses of a licensed vaccine, persons infected or re-infected with Omicron following 2 to 3 doses of a licensed vaccine, and persons infected at least twice with Omicron subvariants.
Research summary

See our other funded research studies

See our other funded research studies